thanks to Labiotech.eu for a great interview with Aurion CEO Greg Kunst!
Are we ready for the first mass-market cell therapy? 📈 Aurion Biotech thinks so! 💉 The American company’s cell therapy candidate treats eye conditions that cause corneal blindness. Its process has the potential to scale to more than 1,000, closing the gap on the global shortage of donor corneas. 👁️ 🎙️ Labiotech has been in conversation with CEO Greg Kunst about how the company aims to improve the standard of care for people with corneal blindness. 🎧 Tune into the latest episode of the Beyond biotech Podcast to find out more! 👇 https://lnkd.in/dCa5yA7c #BeyondBiotechPodcast #celltherapy #cornealblindness #eyecare #healthcareinnovation #medicaladvancements